Anti-THS7A/ THSD7A monoclonal antibody

Anti-THS7A/ THSD7A antibody for FACS & in-vivo assay

Target products collectionGo to THSD7A/THSD7A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1795-Ab-1/ GM-Tg-hg-MP1795-Ab-2Anti-Human THSD7A monoclonal antibodyHuman
GM-Tg-rg-MP1795-Ab-1/ GM-Tg-rg-MP1795-Ab-2Anti-Rat THSD7A monoclonal antibodyRat
GM-Tg-mg-MP1795-Ab-1/ GM-Tg-mg-MP1795-Ab-2Anti-Mouse THSD7A monoclonal antibodyMouse
GM-Tg-cynog-MP1795-Ab-1/ GM-Tg-cynog-MP1795-Ab-2Anti-Cynomolgus/ Rhesus macaque THSD7A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1795-Ab-1/ GM-Tg-felg-MP1795-Ab-2Anti-Feline THSD7A monoclonal antibodyFeline
GM-Tg-cang-MP1795-Ab-1/ GM-Tg-cang-MP1795-Ab-2Anti-Canine THSD7A monoclonal antibodyCanine
GM-Tg-bovg-MP1795-Ab-1/ GM-Tg-bovg-MP1795-Ab-2Anti-Bovine THSD7A monoclonal antibodyBovine
GM-Tg-equg-MP1795-Ab-1/ GM-Tg-equg-MP1795-Ab-2Anti-Equine THSD7A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1795-Ab-1/ GM-Tg-hg-MP1795-Ab-2; GM-Tg-rg-MP1795-Ab-1/ GM-Tg-rg-MP1795-Ab-2;
GM-Tg-mg-MP1795-Ab-1/ GM-Tg-mg-MP1795-Ab-2; GM-Tg-cynog-MP1795-Ab-1/ GM-Tg-cynog-MP1795-Ab-2;
GM-Tg-felg-MP1795-Ab-1/ GM-Tg-felg-MP1795-Ab-2; GM-Tg-cang-MP1795-Ab-1/ GM-Tg-cang-MP1795-Ab-2;
GM-Tg-bovg-MP1795-Ab-1/ GM-Tg-bovg-MP1795-Ab-2; GM-Tg-equg-MP1795-Ab-1/ GM-Tg-equg-MP1795-Ab-2
Products NameAnti-THSD7A monoclonal antibody
Formatmab
Target NameTHSD7A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-THSD7A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species THS7A/ THSD7A VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1795
    Target NameTHSD7A
    Gene ID221981,330267,500032,694787,100686606,101100458,782187,100064843
    Gene Symbol and SynonymsGm837,RGD1566201,THSD7A
    Uniprot AccessionQ9UPZ6
    Uniprot Entry NameTHS7A_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000005108
    Target ClassificationN/A

    The target: THSD7A, gene name: THSD7A, also named as . The protein encoded by this gene is found almost exclusively in endothelial cells from placenta and umbilical cord. The encoded protein appears to interact with alpha(V)beta(3) integrin and paxillin to inhibit endothelial cell migration and tube formation. This protein may be involved in cytoskeletal organization. Variations in this gene may be associated with low bone mineral density in osteoporosis. [provided by RefSeq, Aug 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.